SELLAS Life Sciences Group Inc. (NASDAQ:SLS) stock is trading higher on Thursday. Year-to-date, the stock has surged by around 300%.
FDA Approval Catalyst For Pancreatic Cancer
SLS’s momentum on Thursday may be related to the U.S. Food and Drug Administration (FDA) on Wednesday approving Revolution Medicines Inc.’s (NASDAQ:RVMD) Rasonque (daraxonrasib) for metastatic pancreatic adenocarcinoma (PDAC). Revolution Medicines’ stock is up over 2% on Thursday.
Specifically, it targets patients who previously underwent at least one systemic therapy or those ineligible for multiagent systemic treatment.
Rasonque marks the first approved targeted cancer therapy from a new class of RAS(ON) multi-selective and mutant-selective inhibitors.
SLS009 Preclinical Potential In Solid Tumors
Investors should note that SELLAS is developing SLS009 primarily for earlier-line acute myeloid leukemia (AML) with a potential for expansion into solid cancers.
SLS009 has demonstrated the ability to act as a single agent in PDAC cells largely resistant to leading RAS inhibitors and to synergize with the RAS inhibition mechanism of action.
The data from these preclinical experiments are expected to be presented at an upcoming medical conference.
Phase 2 AML Trial Progress And Milestones
SELLAS also highlighted progress with SLS009, including the launch of an 80-patient Phase 2 study in newly diagnosed AML patients considered unlikely to benefit from standard therapies such as AZA/VEN treatment.
Topline data from the study are expected in the fourth quarter of 2026.
According to SELLAS, the data also showed reductions in MCL-1 and surviving levels following treatment.
SLS Stock Price Activity: SELLAS Life Sciences shares were up 10.38% at $15.15 on Thursday, according to Benzinga Pro data.
Photo: lucadp / Shutterstock – ek
Login to comment